These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Search MEDLINE/PubMed
Title: Effects of 4-aminopyridine and 3,4-diaminopyridine on transmitter release at the neuromuscular junction. Author: Thomsen RH, Wilson DF. Journal: J Pharmacol Exp Ther; 1983 Oct; 227(1):260-5. PubMed ID: 6137556. Abstract: The presynaptic effects of 4-aminopyridine (4-AP) and 3,4-diaminopyridine (3,4-DAP) were investigated at the rat diaphragm neuromuscular junction using intracellular recording techniques. 4-AP caused only minor increases in miniature end-plate potential frequency at junctions depolarized with elevated potassium levels. Calcium ions antagonize this excitatory effect. 4-AP (20-200 microM) enhanced evoked transmitter release and the amplitude of the end-plate potentials (EPPs), but this effect was considerably less than predicted from earlier reports. 4-AP (100 microM) enhanced quantal content of the first EPP by only 97% and 3,4-DAP by 95%. 4-AP and 3,4-DAP also enhanced transmitter release during maintained stimulation at 50 Hz. The APs did not exhaust the output capabilities of the nerve terminal. 4-AP and 3,4-DAP blocked facilitation. This is attributed to the observation that 4-AP and 3,4-DAP increases the statistical probability of release to its maximum level (1.0). Increased transmitter release by 4-AP and 3,4-DAP is attributed primarily to their ability to increase the releasable store of transmitter and mobilization activity. It was observed that 4-AP and 3,4-DAP enhances the duration of the EPP. This observation supports the suggestion that 4-AP prolongs the time course of the presynaptic spike. The effects of 4-AP and 3,4-DAP on quantal release are compatible with the hypothesis that these drugs enhance calcium entry indirectly by blocking voltage sensitive potassium channels.[Abstract] [Full Text] [Related] [New Search]